Intellectual property is a critical element of any life sciences company. It provides an incentive for investment, propels growth, and provides strategic advantages that set companies apart. But IP is also among a company’s most vulnerable assets. As heads of intellectual property work to support the business in advancing the development and use of corporate IP, so too must they find creative solutions to combat countless threats to IP in an ever-evolving complex global marketplace.
Respondents of Consero’s Spring 2020 Life Sciences IP Report include heads of IP from corporations in the medical device, pharmaceutical, and biotechnology industries within the U.S. The 10-question survey yielded responses from 43 participants, providing a glimpse into the challenges facing IP executives in the life sciences community today.